By Stephen Nakrosis PTC Therapeutics on Tuesday offered an update on regulatory activities regarding its Translarna protein restoration therapy in both the.
E Fund Management Co. Ltd. lifted its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 19.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,387 shares of the biopharmaceutical company’s stock after buying an additional 1,655 shares during the […]
E Fund Management Co. Ltd. raised its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 19.0% during the second quarter, HoldingsChannel reports. The fund owned 10,387 shares of the biopharmaceutical company’s stock after acquiring an additional 1,655 shares during the quarter. E Fund Management Co. Ltd.’s holdings in PTC Therapeutics were […]
Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have been given an average recommendation of “Reduce” by the thirteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to […]
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its target price decreased by Barclays from $26.00 to $25.00 in a research note issued to investors on Friday morning, Benzinga reports. Barclays currently has an equal weight rating on the biopharmaceutical company’s stock. Other equities research analysts have also issued research reports about the stock. JPMorgan Chase […]